| 2.135 -0.045 (-2.06%) | 10-12 15:39 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.84 | 1-year : | 3.14 |
| Resists | First : | 2.43 | Second : | 2.69 |
| Pivot price | 2.31  |
|||
| Supports | First : | 2.02 | Second : | 1.68 |
| MAs | MA(5) : | 2.17 |
MA(20) : | 2.35 |
| MA(100) : | 2.44 |
MA(250) : | 1.74 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 19.7 |
D(3) : | 13.9 |
| RSI | RSI(14): 36.7 |
|||
| 52-week | High : | 3.23 | Low : | 0.94 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ FATE ] has closed above bottom band by 12.6%. Bollinger Bands are 38.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.28 - 2.29 | 2.29 - 2.3 |
| Low: | 2.07 - 2.08 | 2.08 - 2.1 |
| Close: | 2.16 - 2.18 | 2.18 - 2.2 |
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating advanced, programmed cellular immunotherapies. These innovative treatments are designed to combat cancer and various immune disorders across the globe. A significant portion of its development pipeline concentrates on NK- and T-cell immuno-oncology programs. Key candidates include FT516, which targets acute myeloid leukemia (AML), B-cell lymphoma, and advanced solid tumors; FT596 for B-cell lymphoma and chronic lymphocytic leukemia; FT538, addressing AML and multiple myeloma; FT576, also focused on multiple myeloma; FT819, aimed at both hematologic malignancies and solid tumors; FT536, another program for solid tumors; and FT500, intended for advanced solid tumors. The company also actively engages in strategic collaborations to advance its research and development. It holds an agreement with Ono Pharmaceutical Co. Ltd. for the joint development and commercialization of two novel, "off-the-shelf" iPSC-derived CAR T-cell therapies. Furthermore, Fate Therapeutics maintains a research collaboration and licensing deal with Juno Therapeutics, Inc., focusing on identifying small molecule modulators that can enhance the therapeutic efficacy of genetically engineered T-cell immunotherapies. A separate collaboration and option agreement exists with Janssen Biotech, Inc. Established in 2007, Fate Therapeutics, Inc. is based in San Diego, California.
Mon, 12 Oct 2026
Fate Therapeutics appoints Jamie Harrell to lead commercialization By Investing.com - Investing.com South Africa
Mon, 12 Oct 2026
Fate Therapeutics appoints Jamie Harrell to lea... - Pluang
Mon, 12 Oct 2026
Fate Therapeutics appoints Jamie Harrell to lead commercialization By Investing.com - Investing.com Canada
Mon, 12 Oct 2026
Three therapies Harrell helped commercialize each topped $1B a year in U.S. sales. He joins Fate Therapeutics. - Stock Titan
Sun, 11 Oct 2026
FATE Stock Jumps 6% As FDA Greenlights Moving Cell Therapy To Clinical Trials - Stocktwits
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 120 (M) |
| Held by Insiders | 1.0548e+008 (%) |
| Held by Institutions | 1 (%) |
| Shares Short | 9,110 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.205e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 495.3 % |
| Return on Equity (ttm) | -26.3 % |
| Qtrly Rev. Growth | 6.49e+006 % |
| Gross Profit (p.s.) | 3.63 |
| Sales Per Share | -24.02 |
| EBITDA (p.s.) | -3.08024e+007 |
| Qtrly Earnings Growth | -1.1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -102 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.09 |
| Price to Cash Flow | 4.09 |
| Dividend | 0 |
| Forward Dividend | 1.076e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|